Sahoo Soumya Swaroop, Kaur Navdeep, Kaur Amandeep, Garg Shivane
Department of Community and Family Medicine, All India Institute of Medical Sciences, Bathinda, Punjab, India.
Assistant Professor, Department of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, 151001, Punjab, India.
Ther Adv Vaccines Immunother. 2022 Sep 17;10:25151355221124018. doi: 10.1177/25151355221124018. eCollection 2022.
Post anti-COVID-19 vaccine lymphadenopathies have been recently described in literature, from different parts of the world. Although there have been studies on lymphadenopathy following mRNA vaccines, there is a paucity of studies on lymphadenopathy following inactivated viral vaccines, such as Covishield.
In this study, we explored lymphadenopathy subsequent to Covishield vaccine in terms of its various ultrasound parameters in the Indian population.
This hospital-based longitudinal study was conducted among 50 adult beneficiaries of Covishield vaccine. Sociodemographic details and relevant clinical history were recorded using a semi-structured performa. Detailed ultrasound (USG) examination of the bilateral axillae was done on the day of vaccination and after 6-12 days post vaccination. Vaccine beneficiaries were evaluated for the presence of any vaccine-associated lymphadenopathy and described the presence, number, size, morphology, cortical thickness, and presence or absence of echogenic hilum.
Out of total (63) lymph nodes evaluated sonologically, majority (80.9%) of lymph nodes showed the features of benign lymphadenopathy. However, 12.6% (8/63) lymph nodes showed diffusely thickened cortex with preserved central echogenic hilum, 4.76% (3/63) lymph nodes showed eccentric cortical thickness with preserved hilar pattern, while only one lymph node showed diffuse cortical thickening with loss of central echogenic hilum.
With an increase in vaccination coverage, clinicians are likely to confront increasing cases of vaccine-associated axillary lymphadenopathy. Therefore, they should exercise care, that contemporary anti-COVID-19 vaccination can present an aetiology of axillary lymph nodes with suspicious USG features.
近期世界各地的文献均报道了接种抗新冠病毒疫苗后出现的淋巴结病。尽管已有关于mRNA疫苗接种后淋巴结病的研究，但对于灭活病毒疫苗（如Covishield）接种后淋巴结病的研究却很少。
在本研究中，我们在印度人群中，从Covishield疫苗接种后淋巴结病的各种超声参数方面进行了探究。
本项基于医院的纵向研究纳入了50名接种Covishield疫苗的成年受种者。使用半结构化表格记录社会人口学细节和相关临床病史。在接种疫苗当天以及接种后6至12天，对双侧腋窝进行详细的超声（USG）检查。对接种疫苗的受种者评估是否存在任何与疫苗相关的淋巴结病，并描述其存在情况、数量、大小、形态、皮质厚度以及是否存在高回声的淋巴结门。
在超声检查评估的总共63个淋巴结中，大多数（80.9%）淋巴结表现出良性淋巴结病的特征。然而，12.6%（8/63）的淋巴结显示皮质弥漫性增厚且淋巴结门高回声保留，4.76%（3/63）的淋巴结显示皮质偏心性增厚且淋巴结门形态保留，而只有一个淋巴结显示皮质弥漫性增厚且中央高回声淋巴结门消失。
随着疫苗接种覆盖率的提高，临床医生可能会面临越来越多与疫苗相关的腋窝淋巴结病病例。因此，他们应谨慎判断，当下的抗新冠病毒疫苗接种可能会导致出现具有可疑超声特征的腋窝淋巴结病因。
